SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protagonist Therapeutics, Inc. – PTGX
May 24, 2022
Pomerantz LLP is investigating claims on behalf of investors of Protagonist Therapeutics, Inc.. Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 7980.
The investigation concerns whether Protagonist and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On April 13, 2022, Protagonist disclosed in a filing with the U.S. Securities and Exchange Commission that “[t]he Company has received a letter from United States Food and Drug Administration (the “FDA”) indicating the FDA’s intent to rescind Breakthrough Therapy Designation for the Company’s rusfertide product candidate in polycythemia vera,” citing “observed malignancies[.]”
On this news, Protagonist’s stock price fell $5.57 per share, or 21.83%, to close at $19.95 per share on April 14, 2022.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
Robert S. Willoughby